UCB (www.ucb.com) is an innovation-driven global biopharmaceutical company focused on the discovery and development of novel medicines and solutions to transform the lives of people living with severe diseases. Thanks to a truly patient-centric approach and a strategy focused on two therapeutic areas, immunology and neurology, UCB is enjoying a period of sustainable growth, with no major patent expiries within the coming decade. In the last years, the company has brought several innovative drugs to patients across the world: Cimzia® (certolizumab pegol) in various arthritis indications and Crohn’s disease, Vimpat® (lacosamide) and Briviact® (brivaracetam) in epilepsy and Neupro® (rotigotine) in Parkinson’s disease and restless legs syndrome. With research collaborations with eminent universities and third parties, UCB enjoys a rich pipeline of future promising drugs and has built one of the most productive R&D organizations in the industry. UCB (www.ucb.com) is an innovation-driven global biopharmaceutical company focused on the discovery and development of novel medicines and solutions to transform the lives of people living with severe diseases. Thanks to a truly patient-centric approach and a strategy focused on two therapeutic areas, immunology and neurology, UCB is enjoying a period of sustainable growth, with no major patent expiries within the coming decade. In the last years, the company has brought several innovative drugs to patients across the world: Cimzia® (certolizumab pegol) in various arthritis indications and Crohn’s disease, Vimpat® (lacosamide) and Briviact® (brivaracetam) in epilepsy and Neupro® (rotigotine) in Parkinson’s disease and restless legs syndrome. With research collaborations with eminent universities and third parties, UCB enjoys a rich pipeline of future promising drugs and has built one of the most productive R&D organizations in the industry.

fermentation